ILiAD Targets UK For Landmark Whooping Cough Vaccine Human Challenge Trial

 
• By Vibha Sharma

ILiAD Biotechnologies explains why it is confident that it will secure approval for the first-ever pivotal Phase III study using a human challenge model for a whooping cough vaccine. Also, it outlines why the UK is the preferred destination for this ground-breaking study.

Pertussis (whooping cough) - Bacterial infection that causes severe coughing fits.
Unpredictable pertussis outbreaks makes traditional Phase III trials nearly impossible (Shutterstock)

More from Clinical Trials

More from Geography